GLP-1 Medications Rise Among Young Adults: Trends and Recommendations

GLP-1 medications such as semaglutide and tirzepatide are increasingly used by younger adults for weight loss and diabetes treatment. A 2024 study published in JAMA revealed that 162,439 young adults aged 18 to 25 received GLP-1 prescriptions in 2023, with women representing 76.4% of these patients. The analysis included both diabetes and weight management prescriptions.

In parallel, the 2025 Monitoring the Future survey found that 2% of students in grades 8, 10, and 12 reported using a prescription GLP-1 medication, while another 2% used it without a prescription.

The influence of GLP-1 medications extends into college campuses, particularly within sorority culture. A feature in The Cut discusses the impact of these drugs on sorority recruitment processes at elite universities.

Three female students, speaking anonymously, noted pressure to meet certain beauty standards, using compounded versions of semaglutide or tirzepatide to enhance their chances during sorority recruitment. Social media and peer weight-loss competitions amplify this trend.

**Jay Campbell**, an expert on longevity and peptides, highlighted the misuse of these drugs as aesthetic shortcuts rather than their intended medical purposes. He cautioned that using them for cosmetic reasons does not address underlying metabolic issues.

Considerations for College Students Using GLP-1 Medications

1. Medical Appropriateness: Evaluate if obesity or metabolic disfunction truly necessitates the use of GLP-1 medications.
2. Muscle Preservation: Incorporate adequate protein intake and resistance training to prevent muscle loss during weight reduction.
3. Fertility Implications: Be aware of fertility and contraceptive interactions with GLP-1 medications. Semaglutide labeling advises discontinuation before a planned pregnancy.
4. Mental Health and Eating Behaviors: Monitor for any mood changes and explore emotional coping mechanisms related to food.
5. Long-term Data Insights: Understand the lack of data on long-term use of GLP-1 in normal-weight individuals starting at a young age.

Campbell emphasized that GLP-1 medications should be considered with the guidance of a qualified prescriber, ensuring evaluation of medical history, monitoring of treatment, and management of side effects. They should not be used as mere lifestyle accessories but treated as part of a comprehensive health strategy.